Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara De Simone

Showing results (161-170 of 213) with videos related to

Pageof 22
Sort By:
Thrombosis and Haemostasis|August 7, 2015
Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) studyMassimo Cugno, Angelo V Marzano, Paolo Bucciarelli, et al.
Journal of Hepatology|August 12, 2009
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasisLuca Miele, Selenia Vallone, Consuelo Cefalo, et al.
Dermatologic Therapy|April 6, 2022
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life studyGiacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual|August 9, 2024
Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio RegionAnnunziata Dattola, Nicoletta Bernardini, Giacomo Caldarola, et al.
HLA|August 2, 2024
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patientsMarco Andreani, Feliciana Mariotti, Anna Pira, et al.
Drugs in Context|July 9, 2026
Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio regionFrancesca Feresin, Nicoletta Bernardini, Elena Campione, et al.
Expert Review of Clinical Immunology|May 19, 2020
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasisPaolo Gisondi, Davide Geat, Andrea Conti, et al.
Vaccines|April 28, 2023
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational StudyFrancesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|October 14, 2020
Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patientsClara De Simone, Laura Calabrese, Anna Balato, et al.
Dermatology (Basel, Switzerland)|April 23, 2025
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive AreasNiccolò Gori, Marco Galluzzo, Andrea Chiricozzi, et al.
Pageof 22

Showing results (161-170 of 213) with videos related to

Sort By:
Pageof 22
Thrombosis and Haemostasis|August 7, 2015
Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) studyMassimo Cugno, Angelo V Marzano, Paolo Bucciarelli, et al.
Journal of Hepatology|August 12, 2009
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasisLuca Miele, Selenia Vallone, Consuelo Cefalo, et al.
Dermatologic Therapy|April 6, 2022
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life studyGiacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual|August 9, 2024
Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio RegionAnnunziata Dattola, Nicoletta Bernardini, Giacomo Caldarola, et al.
HLA|August 2, 2024
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patientsMarco Andreani, Feliciana Mariotti, Anna Pira, et al.
Drugs in Context|July 9, 2026
Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio regionFrancesca Feresin, Nicoletta Bernardini, Elena Campione, et al.
Expert Review of Clinical Immunology|May 19, 2020
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasisPaolo Gisondi, Davide Geat, Andrea Conti, et al.
Vaccines|April 28, 2023
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational StudyFrancesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|October 14, 2020
Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patientsClara De Simone, Laura Calabrese, Anna Balato, et al.
Dermatology (Basel, Switzerland)|April 23, 2025
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive AreasNiccolò Gori, Marco Galluzzo, Andrea Chiricozzi, et al.
Pageof 22